Transferable data exclusivity vouchers are not the solution to the antimicrobial drug development crisis: a commentary on the proposed EU pharma regulation
BMJ Glob Health. 2024 Feb 28;9(2):e014605.
doi: 10.1136/bmjgh-2023-014605.
1 Heidelberg Institute of Global Health (HIGH), University Hospital, Heidelberg University, Heidelberg, Germany astrid.berner-rodoreda@uni-heidelberg.de.
2 Amsterdam Institute for Global Health & Development (AIGHD) and Department of Global Health, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
3 Clinical and Epidemiological Virology, Institute for the Future, Rega Institute for Medical Research, KU Leuven, Leuven, Belgium.
4 Center for Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade Nova de Lisboa, Lisboa, Portugal.
5 Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich, Munich, Germany.
6 Institute for Global Health, University College London (UCL), London, UK.
7 School of Medical and Life Sciences, Sunway University, Bandar Sunway, Malaysia.
8 Medicines Law & Policy, Amsterdam, The Netherlands.
9 Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milano, Italy.
10 Heidelberg Institute of Global Health (HIGH), University Hospital, Heidelberg University, Heidelberg, Germany.
11 Africa Health Research Institute (AHRI), Somkhele and Durban, South Africa.